The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
11192U90 was submitted to receptor binding and monoamine uptake assays. It bound potently at serotonin 5-HT 2 , dopaminergic D 2 , serotonin 5-HT 1A , and adrenergic α 1 and α 2 receptors. It also bound to dopaminergic D 1 , serotonin 5-HT 3 , serotonin 5-HT 4 , and sigma sites, albeit with lower affinity. It was essentially inactive...
1192U90 was developed on the assumption that antagonism of 5-HT 2 receptors efficacy yields more potently than D 2 receptors against positive and negative symptoms of schizophrenia with minimal liability for extrapyramidal side effects (EPSs), and that 5-HT 1A agonism further reduces EPSs and provides anxiolytic and antidepressant activity. 1192U90 was submitted to four...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.